Cgmp manufacturing of LMB-2 immunotoxin
Ended Awarded Last action
- Contract number
- 75N91020F00028
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,021,037
Award facts
- Contract value 100% obligated
- $1,021,037.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21703, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $1,021,037 |
About this award
This is a Cost Plus Fixed Fee delivery order contract awarded by the National Cancer Institute (NCI) to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is for Good Manufacturing Practice (GMP) manufacturing of the LMB-2 immunotoxin, with a ceiling value of $1,021,037.00 and a performance period ending on September 24, 2025. The contract is not set aside for any specific socioeconomic category. Leidos Biomedical Research Inc. is an established Federally Funded Research and Development Center (FFRDC) contractor for NCI, providing a broad range of biomedical research, development, and production services. This task order award is a part of Leidos Biomedical Research Inc.'s larger single-award Indefinite Delivery Contract with NCI, valued at up to $6.6 billion over 5 years, which enables the company to deliver a variety of services to the institute through individual task orders.
Quick answers
Who was awarded contract 75N91020F00028?
75N91020F00028 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 22, 2020.
How much is contract 75N91020F00028 worth?
The government has obligated $1,021,037 on 75N91020F00028.
Is contract 75N91020F00028 an order under another contract?
Yes. 75N91020F00028 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91020F00028 competed?
The extent of competition for 75N91020F00028 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award